References
- Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 national survey on drug use and health (HHS Publication No. PEP21-07-01-003, NSDUH series H-56). Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2021.
- Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2:16065. doi: 10.1038/nrdp.2016.65.
- Mayo Clinic. Depression (major depressive disorder); [cited 2020 Mar 18]. Available from: https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007
- World Health Organization. Depression; [cited 2020 Mar 18]. Available from: https://www.who.int/news-room/fact-sheets/detail/depression
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. Am J Psychiatry. 2006;163(11):1905–1917. doi: 10.1176/ajp.2006.163.11.1905.
- Gaynes BN, Asher G, Gartlehner G, et al. Definition of treatment-resistant depression in the Medicare population. Rockville (MD): Agency for Healthcare Research and Quality; 2018.
- Zhdanava M, Pilon D, Ghelerter I, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2). doi: 10.4088/JCP.20m13699.
- U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic 2019; [cited 2019 Mar 5]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
- Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–438. doi: 10.1176/appi.ajp.2019.19020172.
- Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616–630. doi: 10.1093/ijnp/pyz039.
- Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893–903. doi: 10.1001/jamapsychiatry.2019.1189.
- AMCP Partnership Forum. Optimizing prior authorization for appropriate medication selection. J Manag Care Spec Pharm. 2020;26(1):55–62.
- The National Board of Prior Authorization Specialists (NBPAS). What is Prior Authorization? Oradell. NJ2020 [updated 2020 Dec 15; cited 2022 Dec 23]. Available from: https://www.priorauthtraining.org/prior-authorization/
- Janssen. Supporting appropriate payer coverage decisions. Piscataway (NJ): Johnson & Johnson Health Care Systems Inc.; 2018. p. 1–21.
- Janssen CarePath. Insurance coverage: prior authorization, exceptions, & appeals: Johnson & Johnson Health Care Systems Inc; [updated 2022 Apr 7; cited 2022 April 21]. Available from: https://www.janssencarepath.com/hcp/spravato/insurance-coverage/prior-authorization-exceptions-appeals
- Janssen Pharmaceuticals Inc. SPRAVATO (esketamine) nasal spray prescribing information. Titusville, NJ: Janssen Pharmaceuticals Inc; 2020.
- U.S. Department of Health and Human Services. 45 CFR 46: pre-2018 requirements; [cited 2020 Oct 16]. Available from: https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html#46.101
- Massachusetts General Hospital (MGH). Antidepressant Treatment Response Questionnaire (ATRQ), non-geriatric population, version 2. 2015.
- Massachusetts General Hospital (MGH). Antidepressant Treatment Response Questionnaire (ATRQ), geriatric population, version 3. 2016.
- Gaborcik JW, Groves BK, Palettas M, et al. An ambulatory care clinic and community pharmacy collaboration to address prescription abandonment. Innov Pharm. 2019;10(1). doi: 10.24926/iip.v10i1.1540.
- ClinicalTrials.gov. NCT02782104. A long-term safety study of esketamine nasal spray in treatment-resistant depression (SUSTAIN-3) 2022 [updated 2022 Mar 31; cited 2022 Apr 21]. Available from: https://ClinicalTrials.gov/show/NCT02782104
- American Medical Association (AMA). AMA prior authorization (PA) physician survey. 2022 [cited 2022 Jan 13]. Available from: https://www.ama-assn.org/system/files/prior-authorization-survey.pdf
- Brendle M, Ahuja S, Valle MD, et al. Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study. J Comp Eff Res. 2022;11(18):1323–1336. doi: 10.2217/cer-2022-0149.
- Janssen Pharmaceuticals Inc. Locate your nearest certified outpatient SPRAVATO® treatment center 2022 [updated 2022 Sept; cited 2023 Jan 20]. Available from: https://www.spravatohcp.com/find-a-center
- Samalin L, Rotharmel M, Mekaoui L, et al. Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme. Int J Psychiatry Clin Pract. 2022;26(4):352–362.
- Karkare S, Zhdanava M, Pilon D, et al. Real-world use of esketamine nasal spray among commercially insured patients with treatment-resistant depression. Psych Congress; 2021 Oct 29–Nov 1,; San Antonio, TX, and Virtual.
- Mundi MS, Mercer DF, Iyer K, et al. Characteristics of chronic intestinal failure in the USA based on analysis of claims data. JPEN J Parenter Enteral Nutr. 2022;46(7):1614–1622. doi: 10.1002/jpen.2426.
- Phillips G, Abreu C, Goyal A, et al. Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States. Front Neurol. 2021;12:809999. doi: 10.3389/fneur.2021.809999.